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Purpose. Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors characterized by a myomelanocytic
phenotype, and PEComas occurring in “nonclassic” anatomic distributions are known as perivascular epithelioid cell tumor not
otherwise speciﬁed (PEComa-NOS). This review aims to compile and analyze cases of PEComa-NOS in an eﬀort to better deﬁne
their natural history. Design. We evaluated all 234 cases of PEComa-NOS reported in the English literature, extracting information
regarding diagnostic features, treatment approaches, and outcomes. Multivariate analysis of a number of variables evaluable on
pathologic review was performed to reﬁne preexisting risk stratiﬁcation criteria. Outcomes for patients receiving nonsurgical
treatment are also reported. Results. Primary tumor size ≥5cm(P = 0.02) and a high (1/50HPF) mitotic rate (P<0.0001)
were the only factors signiﬁcantly associated with recurrence following surgical resection. Cytotoxic chemotherapy and radiation
therapy have shown little beneﬁt in treating PEComa-NOS; mTOR inhibition is emerging as a treatment option. Conclusion.
Progress has been made in understanding the natural history and molecular biology of PEComa-NOS. This review further clariﬁes
risk of recurrence in this disease, allowing clinicians to better risk stratify patients. Further work should focus on applying this
knowledge to making treatment decisions for patients with this disease.
1.Introduction
Perivascular epithelioid cell tumors (PEComas) are a collec-
tion of rare tumors deﬁned by the World Health Organi-
zation as “mesenchymal tumors composed of histologically
and immunohistochemically distinctive perivascular epithe-
lioid cells” [1]. In 1991, Pea et al. described the presence
of a unique cell with “prominent cytoplasmic borders and
clear to granular, eosinophilic cytoplasm” in a perivascular
distribution in both angiomyolipoma (AML) of the kidney
and clear cell sugar tumor (CCST) of the lung [2]. The
same group coined the term “perivascular epithelioid cell”
(PEC) for these cells in 1992 and proposed the presence
of this distinctive cell, distinguished in part by strong
HMB-45 positivity, as a common link between a number
of rare disorders in disparate locations, including AML,
CCST, and lymphangiomyomatosis (LAM) of the lung [3].
Despite much controversy regarding the signiﬁcance of PECs
[4], including the fact that no normal counterpart of the
PEC is known, further descriptions of tumors in multiple
anatomic locations composed primarily of these cells has
led to them being designated “PEComas” [5]. PEComas
are notable for a myomelanocytic phenotype, with nearly
all being immunoreactive for both melanocytic (HMB-45
and/or melan-A) and smooth muscle (actin and/or desmin)
m a r k e r s .T h eP E C o m af a m i l yo ft u m o r si sn o wf e l tt ob e
comprised of AML, CCST, LAM, and less well-characterized
PEComas of a variety of other anatomic origins, for which
the term “perivascular epithelioid cell tumor not otherwise
speciﬁed” (PEComa-NOS) has been proposed [6].
PEComa-NOS have been described in a variety of
anatomic locations, including the colon [8, 9], pancreas
[5, 10], retroperitoneum [11, 12], heart [13, 14], adrenal
gland [15], breast [16], eye [17], biliary tract [18], bone
[19], urinary bladder [20, 21], skull base [22], liver [23–25],
uterus [26], cervix [27], skin [28], nasopharynx [29, 30],2 Sarcoma
upper airway [31], and soft tissues [32, 33]. The majority
of the published literature regarding PEComa-NOS is in
the form of case reports and series, with a focus on the
presentation and distinguishing pathologic features of the
disease. In these reports, PEComa-NOS has been given a
variety of titles, including “clear cell sugar tumor,” “primary
extrapulmonary sugar tumor,” “clear cell myomelanocytic
tumor,” and “monotypic epithelioid angiomyolipoma.” This
review aims to compile data from the available literature on
PEComa-NOS with a focus on risk stratiﬁcation and treat-
ment strategies which have been employed in various stages
of the disease. Given improving recognition of PEComa-
NOS and an increasing number of reported cases, this review
aims to build on previously established risk stratiﬁcation
criteria to improve management of patients with this rare
disorder.
2.MaterialsandMethods
2.1. Literature Review. Cases included in this analysis were
retrieved via search of the PubMed database (United States
LibraryofMedicine) forEnglish-languagepublicationsprior
to December 1, 2010. Search terms included “PEComa,”
“perivascular epithelioid cell,” “perivascular epithelioid cell
tumor,” “clear cell sugar tumor,” “primary extrapulmonary
sugar tumor,” “clear cell myomelanocytic tumor,” and
“monotypic epithelioid angiomyolipoma.” Cases of AML,
LAM,andCCST occurring intheirtypicalanatomiclocation
were not included in this analysis. Cases described as
“monotypic epithelioid angiomyolipomas” which occurred
outside the kidney were considered PEComa-NOS; “typical”
AML cases not having monotypic epithelioid features were
not included in this analysis regardless of anatomic location.
Cases which were not considered PEComa-NOS by the
primaryauthors,butwhichhavesubsequentlybeenincluded
in case series based on pathologic ﬁndings [4], were also
included in this analysis. One diﬃculty in deﬁning the
natural history of PEComa-NOS is the large number of
patients who had undergone resection of what was felt to be
ad i ﬀerent entity a number of years earlier and subsequently
presented with PEComa. Unless the initial pathology was
reviewed and felt to be consistent with primary PEComa-
NOS, cases such as this were considered as new cases and not
evidence of recurrence.
2.2. Statistical Analysis. A total of 234 cases in a total of 116
reports were retrieved using the above criteria and reviewed
to obtain demographic information, pathologic details
regarding the primary tumor and outcome data. Statistical
evaluation for risk of recurrence after surgical resection was
performed utilizing JMP v. 9.0.1 (Cary, NC). Univariate
analysis was performed using the Cox proportional hazards
method. Variables deemed signiﬁcant were then analyzed for
correlation; when two variables were highly correlated, the
variablewiththemostsigniﬁcantP-valuewasincludedinthe
multivariate analysis, which was performed using forward
stepwise multiple logistic regression. Multivariate analysis
was performed utilized all noncorrelated variables; given the
large number of cases with missing data points, multivariate
analysis was deemed valid only if there were at least 10 events
for each variable included in the Cox proportional hazard
analysis. The level of signiﬁcance was set at P<0.05.
3. Results
3.1. Review of Reported Cases. Patients ranged in age from
3 to 97 years (median 43 years) and 79% of patients were
female (186/234). When gender-speciﬁc locations (prostate,
uterus) were excluded, the strong female predominance
persisted, with 73% (125/172) of cases occurring in females.
The uterus was the most common anatomic site of origin,
comprising 20% (47) of cases. Other common sites of origin
included the skin (22 cases), liver/falciform ligament (20
cases), retroperitoneum (18 cases), and colon/rectum (16
cases). Tumor size in cases where such information was
reported ranged from 0.5–30cm (mean 6.8cm). Lymph
node involvement was noted in 5 cases, and distant
metastatic disease was present at diagnosis in 6.8% (16/234)
of cases. Local disease was deemed unresectable in 2
additional cases. The most common location for distant
metastatic disease at the time of diagnosis was the lung (5
cases)followedbybone(4cases),withovarian,liver,adrenal,
and peritoneal metastatic disease also reported.
Someformoffollowupwasavailablein81%(189/234)of
cases,withthedurationoffollowuprangingfrom1monthto
>15 years. Information regarding treatment was available in
95%ofcases(222/234);thedegreeoffollowupandtreatment
informationvariedwidely.Atotalof20patientsweredeadof
disease at the time of reporting, comprising 10.6% of cases
with followup information. Of these 20, 7 patients presented
with metastatic or unresectable disease and the other 13 had
recurrence after surgical resection.
3.2. Risk Stratiﬁcation and Outcomes. Folpe et al. [7]
identiﬁed a number of “high-risk” histopathologic features
and integrated them into a set of criteria to risk stratify
PEComas into “malignant,” “uncertain malignant potential,”
and “benign” categories (Table 1). All cases included in this
review were analyzed for presence of these factors and risk
stratiﬁed based on these criteria. Given the fact that not
all cases contained complete reporting on all these high-
risk features, risk status was only able to be conclusively
determined in 40% (93/234) of cases. The large majority
of cases which could be deﬁnitively stratiﬁed using the
criteria (87/93; 94%) were classiﬁed as “malignant,” 6 were
classiﬁed as “benign,” and none were deﬁnitively classiﬁed
as “uncertain malignant potential,” although 30 cases with
partialreporting ofhigh-riskfeaturesmetatleastthislevelof
risk based on size alone. Of the 87 cases deemed “malignant,”
14 had evidence of distant metastases or unresectable disease
at diagnosis. Surgical resection of metastatic disease was felt
to be complete in 3 of these 14 cases in addition to 68 cases
without metastatic disease where the disease was felt to be
completely surgically resected.
In cases with reported followup, a total of 56 cases
(29.6%; 56/189) showed evidence of “malignant behavior,”Sarcoma 3
Table 1: Proposed classiﬁcation of PEComas (adapted from Folpe et al. [7]).
High risk features Risk category
(1) Size >5cm
(2) Inﬁltrative growth pattern
(3) High nuclear grade and cellularity
(4) Mitotic Rate >1/50 HPF
(5) Necrosis
( 6 )V a s c u l a ri n v a s i o n
“Benign”
<2 high risk features and size < 5cm
“Uncertain malignant potential”
Size ≥5cm with no other high risk features OR nuclear
pleomorphism/multinucleated giant cells only
“Malignant”
2 or more high risk features
deﬁned as metastatic or unresectable disease at diagnosis or
recurrenceafterinitialsurgicalresection.Eighteenofthese56
cases presented with metastatic/unresectable disease and 38
had recurrence following what was felt to be complete initial
surgical resection. Of the 38 cases of recurrence, 31 were able
to be fully categorized using the Folpe criteria, and all 31
fell into the “malignant” subgroup. No cases of malignant
behaviorwerenotedinpatientsinthe“benign”or“uncertain
malignant behavior” subgroups, although risk stratiﬁcation
was, as mentioned, incomplete for 7 cases. Only 2 cases of
recurrenceoccurredinpatientswithaprimarytumor<5cm,
and both of these cases demonstrated at least one other high
risk feature. The rate of “aggressive behavior,” deﬁned as
metastatic or recurrent disease, in cases with followup clas-
siﬁed as “malignant” by the Folpe criteria was 51% (39/76),
less than the 71% originally reported by Folpe et al. [7].
In an eﬀort to build on the Folpe criteria for risk
stratiﬁcation focusing on risk of recurrence after what was
felt to be complete surgical resection, Cox proportional
hazard testing was performed for a number of variables,
including those comprising the Folpe criteria. Results of
the univariate analysis are shown in Table 2. Essentially, all
factors except inﬁltration included in the Folpe criteria were
signiﬁcantly associated with an increased risk of recurrence
after surgical resection. Increasing age was also signiﬁcantly
associated with recurrence, and cutaneous primary tumors
were associated with a lower recurrence rate; in fact, no cases
ofcutaneousPEComa-NOSrecurredaftersurgicalresection.
All variables signiﬁcant in the univariate analysis were
then analyzed for correlation in terms of impact on risk
of recurrence. Factors that were signiﬁcantly correlated
included high mitotic rate and high grade (Grade 3);
presence of vascular invasion and necrosis were also sig-
niﬁcantly correlated. Given these correlations, only the
correlated variable with the most signiﬁcant P-value on
univariate analysis (high mitotic rate, necrosis) was included
in the multivariate analysis, which was performed utilizing
a stepwise multiple logistic regression. The results of the
multivariate analysis are presented in Table 3. Only size
>5cm and high mitotic rate were signiﬁcantly associated
with recurrence, although the number of events present in
the analysis was too small to consider this a valid estimate of
risk. Thus, these two variables were analyzed separately, and
they both retained a signiﬁcant association with recurrence
after surgical resection: size ≥5cm (hazard ratio: 4.30, 95%
CI 1.23–27.14, P = 0.02) and high mitotic rate (hazard ratio:
7.56, 95% CI 2.97–23.19, P<0.001). All other variables
included in the initial multivariate analysis were analyzed
sequentially with these two factors; in no analysis were any
of the other factors signiﬁcantly associated with recurrence
or did the two signiﬁcant risk factors lose their association.
Utilizing these two signiﬁcant risk factors for recurrence,
a revised set of risk stratiﬁcation criteria were applied
to the cases reviewed, with cases with a primary tumor
<5cm in size and without a high mitotic rate deﬁned as
“benign,” those with one of these features as “uncertain
malignant potential,” and those with a primary tumor
≥5cm in size and a high mitotic rate as “malignant.” These
criteria were compared with the previously described Folpe
criteria to determine predictive accuracy in this large series
of cases. Only cases where all components of the applied
risk stratiﬁcation criteria were available were included in
the analysis in an eﬀort to avoid underestimating risk of
recurrenceinpatientsmissingdata;theresultsofthisanalysis
are in Table 4.
3.3. Treatment Approaches. 222/234 cases reported some
detailsoftreatment;ofthese,216underwenteitherexcisional
biopsy or surgical resection of the primary tumor. In
cases where surgery was not attempted, the disease was
metastatic at presentation or the primary lesion was felt
to be unresectable. A minority of patients (41/234; 18%)
underwent therapy in addition to surgery, as summarized in
Table 5.
3.3.1. Neoadjuvant Therapy. Six patients underwent neoad-
juvant therapy; 3 were treated with neoadjuvant chemother-
apy alone, 2 with radiation alone, and 1 with chemotherapy
followed by radiation. The clinical and pathologic response
to neoadjuvant therapy in these cases was mixed. Jeon et
al. [34] described a uterine PEComa in a 9-year-old girl
treated with 2 cycles of neoadjuvant vincristine, ifosfamide,
and doxorubicin leading to a 10% reduction in tumor size
on imaging. She subsequently underwent surgical resection;
no signiﬁcant treatment eﬀect was noted on the pathology
specimen. This was followed by concurrent chemoradiation
resulting in no evidence of disease 17 months following
resection, although she did develop acute lymphoblastic4 Sarcoma
Table 2: Univariate analysis of clinical and histologic factors related to PEComa-NOS recurrence.
Variable Recurrence rate Risk ratio 95% CI P-value
Age (continuous variable) 1.02 1.01–1.04 0.01
Size
< 5cm 6/92 (6.5%) 1
≥ 5cm 32/84 (38.1%) 10.74 3.22–66.47 <0.001
Sex
Male 10/37 (27.0%) 1
Female 28/134 (20.9%) 0.85 0.39–2.13 0.70
Mitotic rate
Low 7/93 (7.5%) 1
High (>1/50 HPF) 24/44 (54.5%) 10.0 4.00–30.30 <0.001
Grade
Grade 1-2 9/51 (17.6%) 1
Grade 3 8/19 (42.1%) 3.35 1.17–9.42 0.03
Necrosis
Absent 8/79 (10.1%) 1
Present 25/53 (47.2%) 7.19 3.18–18.38 <0.001
Vascular invasion
Absent 11/52 (21.2%) 1
Present 9/17 (52.9%) 3.22 1.19–8.49 0.02
Inﬁltration
Absent 5/24 (20.8%) 1
Present 7/38 (18.4%) 1.14 0.34–4.41 0.84
Primary location (versus all other sites)
GYN 12/42 (28.6%) 1.37 0.62–2.83 0.42
GI 4/22 (18.2%) 1.69 0.49–4.51 0.24
Skin 0/20(0%)6 . 2 ×10-7 NC 0.002
Liver/Falciform ligament 2/18 (11.1%) 0.34 0.05–1.14 0.09
Retroperitoneal 4/12 (33.3%) 1.32 0.39–3.40 0.61
Table 3: Multivariate analysis of clinical and histologic factors related to PEComa-NOS recurrence.
Variable Risk
ratio 95% CI P-value
(a) All nonconcordant variables Age 1.91 0.15–21.5 0.61
Skin primary 0.0009 0-NC 0.93
Number of events: 24 Size >5cm 6.16 1.04–117.4 0.04
Number of censorings: 83 High mitotic rate (>1/50 HPF) 6.96 2.20–26.7 <0.01
Total number: 107 Necrosis 1.55 0.56–4.70 0.41
(b) Variables signiﬁcant on multivariate analysis Size > 5cm 4.30 1.23–27.2 0.02
Number of events: 25 High mitotic rate (>1/50 HPF) 7.57 2.96–23.2 <0.01
Number of censorings: 93
Total number: 118
leukemia felt to be secondary to exposure to anthracyclines
[35] .T h em o s tr o b u s tr e s p o n s et on e o a d j u v a n tt h e r a p yw a s
described by Osei et al.[37], where 6 cycles of doxorubicin
and ifosfamide led to an 80% decrease in the size of an
upper extremity soft tissue PEComa. This was followed by
neoadjuvant radiation, during which the tumor progressed.
At the time of resection, the tumor showed 20% necrosis.
In other cases utilizing neoadjuvant chemotherapy alone,
progression on therapy [36] and presence of residual viable
tumor [7] have been noted. In cases where neoadjuvant
radiotherapywasutilized[38,39],littleclinicalorpathologic
information was provided to attest to eﬃcacy. Five of these
6 cases were able to be classiﬁed as “malignant” using the
Folpe criteria. The one patient who suﬀered recurrence was
theonlypatienttohaveasigniﬁcantresponsetoneoadjuvant
therapy, as reported by Osei et al. [37].Sarcoma 5
Table 4: Comparison of original and revised Folpe criteria in risk
stratiﬁcation.
Risk category Recurrence following resection
Benign 0/4 (0%) 1/46 (2.2%)
Uncertain
Malignant No cases 3/22 (13.6%)
Potential
Malignant 31/68 (45.5%) 21/30 (70%)
3.3.2. Adjuvant Therapy. A total of 19 patients received
adjuvant therapy, with 7 receiving systemic chemother-
apy, 8 undergoing radiotherapy, and 2 receiving concur-
rent chemoradiation; hormonal therapy (tamoxifen) and
immunotherapy(Interferon-alpha)werebothutilizedinone
case. Information was available to risk stratify 12 of these 19
cases;all12were“malignant”utilizingtheFolpecriteria.The
other cases were unable to be deﬁnitively classiﬁed, but 3 of
thesevenwereatleastof“uncertainmalignantpotential”due
to size alone.
Information regarding adjuvant chemotherapy regimens
was available in 5 reports; the majority of regimens utilized
an anthracycline backbone. Followup was available for 6 of
the 7 patients receiving adjuvant chemotherapy alone; 5 of
these 6 patients had recurrent disease at a median of 21
months of followup (range 2–36 months). Three of these
patients were dead at the time of reporting; two of 8 patients
receiving adjuvant radiotherapy experienced recurrence.
3.3.3. Recurrent/Metastatic Disease. As mentioned above, 38
patients with reported followup had evidence of recurrence;
time to discovery of recurrence ranged from 1–180 months
(median 23 months). Recurrence patterns were diverse, but
the most common sites of recurrence were local (15 cases)
and in the lungs (15 cases). Liver, CNS, and bone metastases
were also frequent, with single reports of metastasis to the
pancreas [55], heart [52], and bladder [55].
Surgical resection of isolated metastatic disease has
been an eﬀective approach in some cases, as a number of
patients were rendered disease-free with surgical resection
alone [56, 57]; multiple patients required serial resections
for recurrent metastases [39, 55]. Only 7 patients received
nonsurgical therapy following recurrence, with 3 receiving
chemotherapy (paclitaxel [51], carboplatin, and epirubicin
[11]), 1 undergoing radiation to a bony metastasis [49], and
3 recently reported cases treated with an mTOR inhibitor
[52, 54]. Only one of these patients was deceased at the time
of reporting; the rest were alive with disease.
A total of 18 patients presented with either metastatic
disease not amenable to resection (16 cases) or unresectable
disease without evidence of distant metastases (2 cases). Of
these 18 patients, 10 underwent nonsurgical therapy, with 3
receiving chemotherapy, 5 undergoing combined chemora-
diation, and 2 receiving an mTOR inhibitor. Followup was
available for 13 of these 18 patients; with 7 of the 13 dead of
disease at a median of 16 months (range 4–30 months).
4. Discussion
4.1. Clinical Features. The results of this review largely
corroborate the results of other large case series investigating
PEComas regarding the clinical features of the disease.
PEComas can occur at the extremes of age, but the median
age of 43 years in this review is consistent with prior series.
A strong female predominance has been a consistent ﬁnding
in PEComa series, and this review conﬁrms that ﬁnding,
although the approximately 4:1 female-to-male ratio is
slightly less than that noted in earlier series [7, 58]O n e
potential reason for this is an increase in the number of
extragynecologic PEComas being recognized, as only 24%
(56) of the cases reviewed here were gynecologic in origin
as compared to approximately 40% in earlier series [7, 59].
Increased recognition of the PEComa family of tumors has
likely led to improved characterization of these tumors in
unusual locations, whereas they may have been mischarac-
terized as melanoma or soft tissue sarcoma in the past.
4.2. Risk Stratiﬁcation. Folpe et al. [7] established criteria
for determining malignant potential of PEComas in 2005
(Table 1). These criteria have been applied in multiple subse-
quently reported cases, although the role of these criteria in
guiding management remains unclear. Information to allow
forcompleteapplicationofthesecriteriawasavailableinonly
40% of reviewed cases, making drawing conclusions from
this data diﬃcult. However, the available data do allow for
further evaluation of the criteria in predicting recurrence
following what is felt to be complete resection of a PEComa-
NOS. Of the 38 cases of recurrence in this review, 31 (82%)
were classiﬁed as malignant using these criteria. Information
required for complete risk stratiﬁcation was incomplete in
the remaining seven patients with reported recurrence, but
3 of these 7 cases were categorized as having “uncertain
malignant potential” due to size ≥5cm alone. With full
reporting of all high-risk criteria, these cases may have been
recategorized into the “malignant” group. No documented
recurrence occurred in any patient with a primary tumor
<5cm in greatest diameter without an additional high risk
feature.Theseﬁndingsprovidesupportforthebenignnature
of PEComa-NOS which are <5cm in size without any other
high-risk features as deﬁned by the Folpe criteria.
In evaluating the multivariate analysis and revised risk
stratiﬁcation criteria utilizing only size ≥5cm and high
mitotic rate as contributing risk factors, it is diﬃcult to draw
signiﬁcant conclusions given the lack of reporting of these
variablesinanumberofcases.Inevaluablepatients,presence
of both of these factors predicted a higher risk of recurrence
following surgical resection, while the absence of either of
these high risk features appears to be associated with a very
small risk of recurrence, and thus utilizing these two factors
as the primary determinants of risk may simplify the risk
stratiﬁcation and counseling process in the postoperative6 Sarcoma
Table 5: Reported cases of non-surgical treatment of PEComa-NOS.
Reference/year Age/Sex Location Size (cm) Folpe cat. Management Outcome Treatment details
Neoadjuvant cases
Folpe et al. [7] 49F Shoulder N/A Malignant NA CT, resection NED at
11mo
Ifos/Adria—residual
dz at resection
Jeon and Sung [34]a n d
Jeon and Yi [35] 9F Uterus 6.5 Malignant NA CT, resection,
Adj CT
NED at
16mo; ALL
diagnosed at
16mo
Vincr/Ifos/Adria—2
NA cycles, 6 adj cycles
concurrent with
45Gy.
Ong et al. [36] 8F Vagina 2 Unknown NA CT, resection NED at 6mo Ifos/Vincr/Actino D
x3—prog
Osei et al. [37] 49F UE soft tissue 5.3 Malignant
Sequential NA CT
then RT followed
by resection
Single lung
metastasis at
14mo—
resected
Ifos/Adria x6—80%
reduction, then 50Gy
RT—prog
Weinreb et al. [38] 68M Thigh 7.8 Malignant NA RT, resection NED at
11mo
Yamashita et al. [39] 39F Tibia 6.5 Malignant NA RT, resection NED at
34mo
Adjuvant Cases
Bosincu et al. [40] 48F Uterus 7 Malignant Resection, Adj HT NED at
36mo Tamoxifen
Chen et al. [41] 16F Abdominal 27 Malignant Resection, Adj CT
Recurrence at
2mo;no
further
follow-up
(+) LN at surgery
Fink et al. [42] 51F Broad Lig 17 Unknown Resection, Adj RT NED at
15mo 50.4Gy
Folpe et al. [43] 29M Falciform Lig 20 Malignant Resection, Adj RT
Lung
metastases at
3mo;deadof
other causes
at 1yr
Folpe et al. [43] 10F Falciform Lig 5 Unknown Resection, Adj CT Lost to
follow-up
Vincr, Actino D,
Cyclophos
Folpe et al. [7] 71M Forearm 9 Malignant Resection, Adj RT NED at
10mo
Folpe et al. [7] 48F Cervix 2 Unknown Resection, Adj RT NED at
21mo
Folpe et al. [7] 77F Neck 2.6 Unknown Resection, Adj RT NED at 6mo
Folpe et al. [7] 56F Uterus 9 Malignant Resection, Adj CT
and RT
Lung and
bony
metastases at
11mo; alive
at 11mo
Folpe et al. [7] 59F Uterus 14.5 Malignant Resection, Adj CT
Liver and
lung
metastases at
30mo; alive
at 30mo
Folpe et al. [7] 46F Mesentery 12 Malignant Resection, Adj CT
Intra-
abdominal
and liver
metastases at
22mo; DOD
at 27mo
“Multiple” cycles of
adjuvant CTSarcoma 7
Table 5: Continued.
Reference/year Age/Sex Location Size (cm) Folpe cat. Management Outcome Treatment details
Folpe et al. [7] 36F Uterus N/A Malignant Resection, Adj CT
Lung
metastases at
12mo, liver
metastases at
36mo; DOD
at 39mo
Hornick and Fletcher [11] 50F Pelvis 13 Malignant Resection, Adj RT
Lung, liver,
abdominal
wall
metastases at
39mo, alive
at 46mo
Pan et al. [20] 46M Prostate 8.5 Malignant Resection, Adj RT
Pulmonary
metasases at
3y r s ,D O Da t
4y r s
Cis/Adria x6 cycles
Parﬁtt et al. [44] 48M Bladder 3 Unknown Resection, Adj IT NED at
48mo IFN-α
Ryan et al. [45] 15F Rectum 3.7 Malignant Resection, Adj CT NED at 9mo (+) LN at surgery;
Ifos/Adria
Silva et al. [4] 76F Uterus N/A Malignant Resection, Adj RT NED at 8mo
Subbiah et al. [46] 58F Retroperitoneal 17 Unknown Resection, Adj CT
Liver
metastases at
2y r s ,
resected with
subsequent
liver and lung
metastases
2c y c l e sa d jA d r i a ;
RT/adria after
resection of liver
recurrence; tem-
sirolimus/bortezomib
at 2nd
recurrence—prog
Vang and Kempson [47] 75F Uterus 5 Unknown Resection, Adj RT NED at
30mo
Metastatic/Recurrent Cases
Bonetti et al. [48] 19F Uterus 5.5 Malignant
Subtotal resection
of primary, CT
followed by RT
Local
recurrence at
10mo,
diﬀuse
metastatic
disease at
18mo
L´ eon et al. [49] 76F Abdominal 15 Malignant RT to sacral
recurrence
Progressive
metastatic
disease
13Gy RT to sacrum
L´ eon et al. [49] 38F Retroperitoneal N/A Malignant CRT DOD at
20mo RT/Thal
Fukunaga et al. [50] 40F Uterus 30 Malignant Debulking surgery,
CRT
DOD at
17mo
Mulitple omental
metastases at initial
surgery
Greene et al. [51] 79F Uterus 13 Malignant
Debulking of
pelvic recurrence,
CT
DOD at
“several” mo Paclitaxel x1 cycle
Italiano et al. [52] 55F Uterus N/A Unknown
Resection of
recurrence, CT,
CRT following 2nd
recurrence, mTOR
following
progression
Progressive
metastatic
disease; alive
at 16mo
following
recurrence
Ifos/Adria, RT+etop,
Temsirolimus, Gem
Italiano et al. [52] 69F Uterus N/A Unknown
mTOR, resection
of solitary lung
metastasis
NED at 9mo
Temsirolimus;
response allowed
surgical resection8 Sarcoma
Table 5: Continued.
Reference/year Age/Sex Location Size (cm) Folpe cat. Management Outcome Treatment details
Peng et al. [53] 47M Pelvis 12 Malignant Subtotal resection
of primary, CT DOD at 9mo
Ifos/Epi x2—prog;
Adria/Oxali/Thal x
2—prog; Nada,
Dacarb x2—prog
Silva et al. [4] 47F Uterus N/A Malignant
Resection of
primary; RT
followed by CT
DOD at
30mo
Lung metastases at
diagnosis; Adria/Cis
x8 cycles
Silva et al. [4] 73F Uterus N/A Malignant Resection of
primary; CT DOD at 9mo Paclitaxel x6 cycles
Silva et al. [4] 43F Uterus N/A Malignant Resection of
primary; CT
Alive with
progressive
disease at
6mo
Ifos/Adria x5 cycles
Wagner et al. [54] 70M Kidney 9 Unknown
TKI, mTOR
inhibitor, resection
of recurrence
40%
reduction in
size of
isolated
recurrence,
NED after
resection
Sunitinib, sirolimus
Wagner et al. [54] 65M Retroperitoneal 20 Malignant
Resection of
recurrences,
mTOR inhibitor
“Near
complete dis-
sapperance”
of multifocal
disease at
12mo, alive
at 16mo
following
recurrence
Sirolimus
Wagner et al. [54] 61F Cervix 9 Malignant mTOR inhibitor
Initial
response,
DOD at 8mo
Sirolimus
Yamashita et al. [39] 35M Vertebral 1.8 Malignant CRT
Bone
metastases at
9mo,aliveat
12mo
Pelvic mets—no tx
details
Yamashita et al. [39] 42F Uterus 15 Malignant
Resection of
humeral
recurrence, CT
DOD at
10mo with
diﬀuse
metastases
Legend: NA: Neoadjuvant, Adj: Adjuvant, CT: Chemotherapy, RT: Radiation therapy, IT: Immunotherapy, HT: Hormonal therapy, NED: No evidence of
disease, DOD: Dead of disease, Ifos: Ifosfamide, Adria: Doxorubicin, Vincr: Vincristine, Actino D: Actinomycin D, CTX: Cyclophosphamide, Cis: Cisplatin,
Thal: Thalidomide, Epi: Epirubicin, Oxali: Oxaliplatin, Nada: Nadplatin, Dacarb: Dacarbazine, Etop: Etoposide, Gem: Gemcitabine, TKI: Tyrosine kinase
inhibitor.
setting. In practical terms, no risk stratiﬁcation schema
has been uniformly applied to guide decisions regarding
adjuvant therapy, and continuing work will need to be done
evaluating all potential adverse risk factors reported here
as well as others yet to be described. Uniform reporting of
all histologic features utilized in the Folpe criteria will no
doubt be beneﬁcial in eﬀorts to further clarify such risk
stratiﬁcationcriteria,asonly40%patientsinthisreviewwere
truly evaluable given incomplete reporting of these variables.
Given this fact, applicability of the risk stratiﬁcation we
propose based on this data is limited; future series with more
completereportingwillallowforimprovedstatisticalanalysis
and may lead to a diﬀerent set of risk stratiﬁcation criteria.
4.3. Treatment Approaches. This review demonstrates the
wide variety of treatment approaches utilized in PEComa-
NOS, as well as the lack of consensus regarding treatment
strategies. No treatment approachhas been shown to be con-
sistently eﬀective in this disease, although such a conclusion
is certainly premature given the numbers of patients who
have received treatment and the lack of randomized dataSarcoma 9
available. One signiﬁcant issue in the nonsurgical treatment
of PEComa is that many cases are not diagnosed conclusively
as PEComa until after surgical resection, limiting available
treatment approaches.
Neoadjuvant treatment has been utilized in a small
number of cases with only one report of a robust objec-
tive response to therapy; other cases utilizing neoadjuvant
therapy report either progression or minimal evidence
of eﬃcacy in the resected tumor. The role of adjuvant
therapy for PEComa-NOS is also unclear, and this series
does little to change that. When reported, chemotherapy
regimens utilized were typically similar to those used in soft
tissue sarcomas with an anthracycline backbone, but many
diﬀerent variations were reported. The rate of recurrence
(45%) and death from disease (15%) are much higher in this
group than the series as a whole. This phenomenon has been
noted in at least one other review of gynecologic PEComas
[60], where receipt of postoperative therapy was associated
with an increased rate of recurrence. No deaths appeared to
be directly attributable to therapy, and it is most likely that
the increased rates of recurrence and death in this group are
due to selection of patients with extremely high-risk disease
for adjuvant therapy as opposed to intrinsic harm from the
treatment.
In the metastatic setting, systemic chemotherapy has
shown little eﬃcacy, as there were no objective responses
reported with the use of chemotherapy in this review. The
unpredictability of the natural history of PEComa-NOS,
even in the metastatic setting, is also illustrated by the
number of patients rendered NED by surgical resection of
oligometastatic disease as well as reports of survival for up to
one year without progression of disease in the absence of any
therapy [61].
Targeted therapies, most notably mTOR inhibitors, have
been a recent development in the treatment strategy of all
members of the PEComa family, including PEComa-NOS.
Thisinterestinitiallyarosefromtheobservationthatpatients
with tuberous sclerosis complex (TSC) have a higher rate of
LAM and AML than the general population [62, 63]. TSC is
an autosomal dominant genetic disease due to loss of either
the TSC1 (9p34) or TSC2 (16p13.3) genes; a number of
diﬀerent mutations in either of these genes leads to the TSC
phenotype [64, 65]. LAM is present in 25–35% of female
patients with TSC [62, 66], 50–80% of adults with TSC have
renal AMLs [63, 67, 68], and the two diseases are frequently
both present in those with TSC [63]. Given this link between
TSC, LAM, and AML, the role of TSC1/TSC2 mutations
in the pathogenesis of these diseases has been vigorously
investigated [69].
Germline loss of heterozygosity (LOH) at the TSC2 locus
has been demonstrated in TSC-associated AML [70–72]a n d
LAM [73]; LOH at the TSC1 locus has been less frequently
described. TSC1 and TSC2 code for separate proteins which,
after interaction, regulate cell proliferation via the mTOR
pathway [74]. Complete loss of either TSC1 or TSC2 due to a
secondhit toeitherTSC locusleadstoadysfunctionalTSC1-
TSC2 complex and unchecked cell proliferation through
unregulated mammalian target of rapamycin complex 1
(mTORC1) activation [75] and impaired mammalian target
of rapamycin complex 2 (mTORC2) activation [76]. Given
the role of the mTOR pathway in these disorders, mTOR
inhibition has been viewed with great enthusiasm as a
potential treatment modality, and this enthusiasm has been
matched by meaningful responses to mTOR inhibition in
both AML and LAM [41, 77, 78].
The proportion of patients with PEComa-NOS and TSC
is not as large as that linking TSC and LAM or AML [7],
but genetic analysis of multiple PEComa-NOS specimens
have demonstrated activation of the mTOR pathway [79,
80], indicating potential beneﬁt for mTOR inhibition in
PEComa-NOS. To date, the reported experience utilizing
mTOR inhibition in PEComa-NOS is limited to a handful
of case reports and series [46, 52, 54]. These series, however,
have been promising in that signiﬁcant responses [52],
including at least one long-term response (16 months)[54],
have been reported. Responses have not been uniform, how-
ever [46], and further clinical trial data must be accumulated
before deﬁning the role of mTOR inhibition in metastatic
or recurrent PEComa-NOS. Clinical trials evaluating mTOR
inhibitors in LAM and AML are currently accruing; it is
unlikely given their rarity that PEComa-NOS treatment will
be evaluated separately in a randomized fashion, so use of
mTOR inhibitors in this setting will likely be in the setting of
Phase I trials and/or oﬀ-label based on results of the above-
mentioned trials in AML and LAM.
Given the available data in the literature, no deﬁnitive
treatment strategy can be unequivocally recommended at
this time. In the opinion of the authors, neoadjuvant therapy
has its only role with a goal of conversion of unresectable
disease to resectable, although little data supports the
eﬃcacy of such an approach. Adjuvant therapy may be of
beneﬁt in patients at high risk of recurrence, but given
only approximately half of patients with disease classiﬁed
as malignant by Folpe criteria will experience recurrence
following resection, exposing patients to the risk of systemic
chemotherapy without a known beneﬁt is a major concern.
Regardlessofthepostoperativestrategyemployed,long-term
surveillance should be at its core, as multiple recurrences
have been reported >5 years after surgical resection [52, 57,
81, 82]. Early detection of recurrence may allow for surgical
resection of solitary lesions or oligometastatic disease, which
hasbeeneﬀectiveinlongtermcontrolofdiseaseinanumber
of reported cases. Given the lack of beneﬁt of traditional
cytotoxic therapy in the metastatic setting, mTOR inhibition
in the setting of a clinical trial should be strongly considered
in any patient with recurrent or metastatic disease. This
approach is as yet unproven in the adjuvant setting or
following resection of metastatic disease, but mTOR inhibi-
tion is emerging as an attractive treatment option as more
information on its use in LAM and AML returns.
5. Conclusion
PEComa-NOS remains a rare, but increasingly recognized
entity and much progress has been made in unraveling
the molecular mechanisms underlying this disease and
other members of the PEComa family. Evaluation of risk10 Sarcoma
of aggressive behavior remains an imprecise undertaking
given the diverse array of clinical behavior noted in the
literature, but this analysis suggests that tumor size and
high mitotic rate are the best predictors of recurrence
after surgical resection. The Folpe criteria continue to have
utility, especially in helping to categorize lesions as having
low malignant potential. This review better deﬁnes the
naturalhistoryofPEComa-NOSofvariousprimarysitesand
outlines the importance of long-term surveillance, given a
n u m b e ro fc a s e so fl a t er e c u r r e n c e .I d e a lt r e a t m e n ts t r a t e g i e s
remainundeﬁned,butanemergingroleformTORinhibitors
raises enthusiasm in the treatment of these rare tumors.
Clinicians should be aware of this new treatment paradigm
and work to ensure clinical trials to further deﬁne the role of
mTOR inhibitors are embraced.
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